72.73
Schlusskurs vom Vortag:
$74.06
Offen:
$72.69
24-Stunden-Volumen:
119.99K
Relative Volume:
0.83
Marktkapitalisierung:
$515.56M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-4.98M
KGV:
-55.19
EPS:
-1.3177
Netto-Cashflow:
$-3.85M
1W Leistung:
+9.93%
1M Leistung:
+41.80%
6M Leistung:
+163.99%
1J Leistung:
+71.90%
Bright Minds Biosciences Inc Stock (DRUG) Company Profile
Firmenname
Bright Minds Biosciences Inc
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie DRUG mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
|
DRUG
Bright Minds Biosciences Inc
|
72.73 | 524.98M | 0 | -4.98M | -3.85M | -1.3177 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Bright Minds Biosciences Inc Stock (DRUG) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-08 | Eingeleitet | BTIG Research | Buy |
| 2025-05-13 | Eingeleitet | TD Cowen | Buy |
| 2025-05-07 | Eingeleitet | Chardan Capital Markets | Buy |
| 2025-01-23 | Eingeleitet | Piper Sandler | Overweight |
| 2025-01-10 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2025-01-10 | Eingeleitet | H.C. Wainwright | Buy |
| 2024-11-26 | Eingeleitet | Robert W. Baird | Outperform |
Alle ansehen
Bright Minds Biosciences Inc Aktie (DRUG) Neueste Nachrichten
Bright Minds Biosciences (NASDAQ:DRUG) Cut to Hold at Zacks Research - Defense World
Why Bright Minds Biosciences Inc. stock attracts high net worth investorsPortfolio Growth Summary & Fast Gaining Stock Strategy Reports - Newser
Bright Minds Biosciences (NASDAQ:DRUG) Sees Unusually-High Trading VolumeShould You Buy? - MarketBeat
Cantor Fitzgerald Analysts Lower Earnings Estimates for DRUG - MarketBeat
An Intrinsic Calculation For Bright Minds Biosciences Inc. (CSE:DRUG) Suggests It's 44% Undervalued - simplywall.st
Bright Minds Biosciences (NASDAQ:DRUG) Targets Neurological Disorders - Kalkine Media
DRUG FY2025 EPS Estimate Decreased by Cantor Fitzgerald - Defense World
(DRUG) and the Role of Price-Sensitive Allocations - news.stocktradersdaily.com
Bright Minds Biosciences (NASDAQ:DRUG) Shares Up 7.2%Still a Buy? - MarketBeat
What technical signals suggest for Bright Minds Biosciences Inc. stockJuly 2025 Patterns & Reliable Volume Spike Alerts - Newser
Cantor Fitzgerald reiterates Overweight rating on Bright Minds Biosciences stock - Investing.com Nigeria
Bright Minds Biosciences (NASDAQ:DRUG) Reaches New 1-Year HighTime to Buy? - MarketBeat
How institutional buying supports Bright Minds Biosciences Inc. stockPortfolio Performance Report & High Accuracy Investment Signals - moha.gov.vn
What drives Bright Minds Biosciences Inc stock priceConsumer Goods Stocks & Free Rapid Wealth Multiplication - earlytimes.in
How Bright Minds Biosciences Inc. stock performs in high volatility markets2025 Year in Review & Consistent Growth Equity Picks - BỘ NỘI VỤ
Will Bright Minds Biosciences Inc. stock deliver shareholder valueMarket Trend Report & Technical Pattern Based Signals - moha.gov.vn
Recent Price Trend in Bright Minds Biosciences Inc. (DRUG) is Your Friend, Here's Why - sharewise.com
Brokerages Set Bright Minds Biosciences Inc. (NASDAQ:DRUG) Target Price at $81.00 - Defense World
Bright Minds Biosciences to Present at Piper Sandler 37th Annual Healthcare Conference and 2025 AES Annual Meeting - The Manila Times
Bright Minds (NASDAQ: DRUG) to Present at Piper Sandler Event, 2025 AES Meeting - Stock Titan
Wall Street Analysts Think Bright Minds Biosciences Inc. (DRUG) Could Surge 36.27%: Read This Before Placing a Bet - sharewise.com
FY2025 Earnings Forecast for DRUG Issued By Chardan Capital - MarketBeat
Bright Minds Biosciences Inc. (NASDAQ:DRUG) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Responsive Playbooks and the DRUG Inflection - news.stocktradersdaily.com
Bright Minds Biosciences (NASDAQ:DRUG) Upgraded at Chardan Capital - Defense World
Bright Minds Biosciences (NASDAQ:DRUG) Rating Increased to Strong-Buy at Chardan Capital - MarketBeat
Bright Minds Biosciences Inc. (DRUG) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Will Bright Minds Biosciences Inc. stock outperform international peers2025 Earnings Impact & Fast Moving Trade Plans - newser.com
Does Bright Minds Biosciences Inc. stock trade at a discount to peersPortfolio Gains Report & Step-by-Step Trade Execution Guides - newser.com
Can Bright Minds Biosciences Inc. stock beat market expectations this quarterJuly 2025 Spike Watch & Real-Time Chart Breakout Alerts - newser.com
Bright Minds Biosciences Inc. stock prediction for this weekMarket Activity Report & Daily Profit Focused Screening - newser.com
Can Bright Minds Biosciences Inc. rally from current levelsWeekly Trend Recap & Capital Efficient Trade Techniques - newser.com
Is Bright Minds Biosciences Inc. stock a safe investment in uncertain markets - newser.com
Bright Minds Biosciences Strengthens Advisory Board with PWS Experts - MSN
Multi factor analysis applied to Bright Minds Biosciences Inc.2025 Geopolitical Influence & Daily Chart Pattern Signals - newser.com
Why Bright Minds Biosciences Inc. stock remains undervalued - newser.com
Is it time to cut losses on Bright Minds Biosciences Inc.Trade Ideas & Safe Swing Trade Setup Alerts - newser.com
Using Python tools to backtest Bright Minds Biosciences Inc. strategies2025 Price Targets & Smart Allocation Stock Reports - newser.com
What earnings revisions data tells us about Bright Minds Biosciences Inc.July 2025 Highlights & Free Long-Term Investment Growth Plans - newser.com
What machine learning models say about Bright Minds Biosciences Inc.Stock Surge & AI Driven Price Predictions - newser.com
Finanzdaten der Bright Minds Biosciences Inc-Aktie (DRUG)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):